Latest research on Pemetrexed

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.

Pemetrexed side effects

The dose of Pemetrexed was decreased in two patients (4%). [source, 2016]
Therefore, Pemetrexed is increasingly used whether as part of the first-line platinumbased doublet or as maintenance therapy, and its availability in the second-line setting has decreased for patients with non-squamous histology. [source, 2016]
Moreover, Docetaxel caused a higher rate of grade 3/4 toxicity as second-line treatment in neutropenia and febrile neutropenia compared with Pemetrexed, whereas a lower rate of thrombocytopenia and no difference in anemia and non-hematological toxicity were observed (Table 3). [source, 2015]
In cell line experiments, Pemetrexed increased EGFR phosphorylation and reduced Akt phosphorylation, which ultimately enhanced the sensitivity of the tumor to EGFR TKIs. [source, 2015]
Furthermore, Erlotinib was found to increase the expression of Thymidylate synthase and, subsequently, enhance the sensitivity of tumor cells to Pemetrexed. [source, 2015]
We selected Pemetrexed because it is a relatively recent developed drug compared to Paclitaxel, Docetaxel, Vinorelbine, or Gemcitabine, and has a greater anti-cancer efficacy for a subset of non-small cell lung carcinoma. [source, 2015]
First, only 10 of the 21 patients received second-line or further treatment because EGFR-TKI and Pemetrexed were not widely available in China at that time of our study. [source, 2015]
After 2 cycle of Pemetrexed and Cisplatin combination chemotherapy, pleural effusion was decreased on chest radiograph and dyspnea was improved. [source, 2015]
However, immunohistochemistry results demonstrated malignant mesothelioma, and neoplasm's size had decreased after Pemetrexed and Cisplatin combination chemotherapy. [source, 2015]
Nintedanib also had an acceptable and manageable safety profile in combination with Pemetrexed, with the most frequent adverse events being reversible increases in aspartate aminotransferase and Alanine aminotransferase and gastrointestinal events.32 [source, 2015]